Related Experiment Video
Updated: May 5, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
34.4K
Combined long-acting bronchodilator single therapy for COPD.
Ruxandra Mioara Râjnoveanu1, Sabina Antoniu, Ruxandra Ulmeanu
1University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj-Napoca, Faculty of Medicine-Pulmonary Disease , 6 B.P. Hasdeu Street, Cluj-Napoca, 400371 , Romania.
Expert Opinion on Pharmacotherapy
|November 29, 2013
Summary
Combined long-acting bronchodilators, like glycopyrronium+indacaterol, offer superior, sustained bronchodilation for COPD patients. This improves respiratory symptoms and overall health status compared to single agents or placebo.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Chronic Obstructive Pulmonary Disease (COPD) management often requires bronchodilators.
- Existing long-acting bronchodilators may not consistently provide adequate bronchodilation amplitude or duration.
- This limitation can lead to exacerbated respiratory symptoms and diminished health status in COPD patients.
Purpose of the Study:
- To evaluate the efficacy and safety of a novel combination inhaler.
- To compare the effects of glycopyrronium+indacaterol single inhaler (QVA149) against its individual components, tiotropium, and placebo.
Main Methods:
- A 26-week clinical study was analyzed.
- The study design involved multiple treatment arms including QVA149, glycopyrronium, indacaterol, tiotropium, and placebo.
Main Results:
- The combination therapy demonstrated superior bronchodilator effects.
- Sustained bronchodilation was observed with the combined inhaler.
- Respiratory symptoms associated with bronchoconstriction were minimized.
Conclusions:
- Combination therapy with glycopyrronium+indacaterol provides enhanced and lasting bronchodilation.
- This approach effectively addresses limitations of single long-acting bronchodilators in COPD.
- The combination therapy can significantly improve COPD patient outcomes by reducing symptom severity.
More Related Videos
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
01:24Chronic Obstructive Pulmonary Disease
3.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.2K
01:23Inhaled Medications
1.1K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
4.0K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.0K